Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong David Kleinman?

David M. Kleinman

Chief of Ophthalmology

Denver Health

HQ Phone:  (303) 436-6000

Email: d***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Denver Health

777 Bannock Street MC 0278

Denver, Colorado,80204

United States

Company Description

Denver Health is the Rocky Mountain Region's Level 1 academic trauma center, and the safety net hospital for the Denver area. The Denver Health system, which integrates acute and emergency care with public and community health, includes the Rocky Mountain Regi... more.

Find other employees at this company (4,692)

Background Information

Employment History

Chief Medical Officer

ONL Therapeutics Inc


Associate Professor of Ophthalmology (Part Time)

Flaum Eye Institute at the University of Rochester


Chief Executive Officer

Eyeon Therapeutics, Inc.


Web References(36 Total References)


Management – ONL Therapeutics

www.onltherapeutics.com [cached]

David M. Kleinman, M.D., M.B.A., Chief Medical Officer
Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute. In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.


www.specialtypharma.com

Dr. David M. Kleinman
President, CEO & Co-Founder Eyeon Therapeutics, Inc. Dr. David M. Kleinman is President, CEO, and Co-founder of Eyeon Therapeutics, Inc., an early stage ophthalmology firm developing novel technologies to treat eye diseases. Eyeon Therapeutics and Particle Sciences, Inc. have formed a joint venture to commercialize PEGPLUSTM as an improved therapy for dry eye syndrome. Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery, and he also serves as a part-time Associate Professor of Ophthalmology at the Flaum Eye Institute at the University of Rochester. In addition to running Eyeon Therapeutics and working at the Flaum Eye Institute, he consults for biotechnology, medical device, pharmaceutical, and investment firms nationally. He has helped multiple start-ups develop intellectual property, generate preclinical data, raise money, submit regulatory filings, and complete proof-of-principle and Phase I clinical trials. He also assists larger companies with due diligence and pharmaceutical development in ophthalmology. He is the former Chief of Ophthalmology at Denver Health Medical Center in Denver. He earned his BA from Brown University, his MD with honors from the University of Colorado School of Medicine, and graduated as a Dean's Scholar from the Simon School of Business.


Eyeon Therapeutics Out-Licenses Proprietary OTC Dry Eye Product

www.prnewswire.com [cached]

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "We are grateful to Particle Sciences for their support in helping us develop and advance this important new technology designed to provide a better treatment opportunity for dry eye patients, and we are delighted to have found an excellent commercial organization to bring this technology to patients with dry eye disease in North America.


ois.net

David Kleinman, Associate Professor of Ophthalmology - Flaum Eye Institute


www.reviewofophthalmology.com

David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory